Skip to main content
. 2021 May 11;13(10):2290. doi: 10.3390/cancers13102290

Figure 3.

Figure 3

Comparison of the changes in the circulating tumor cell (CTCs) status between the patients who developed progressive disease (PD) between weeks 4 and 8 (n = 13) and who continued to benefit from nivolumab treatment (non-PD) beyond week 8 (n = 16). The increased vs. decreased or equal of each CTC status in PD patients was compared between the baseline and at the point of disease progression and, in non-PD patients, was compared between the baseline and at week 8. The association of changes in (a) the total number of CTCs, (b) number of programmed death-ligand 1 (PD-L1)-positive CTCs, and (c) PD-L1 positivity rates upon nivolumab treatment were compared between the PD and non-PD patients. Orange indicates that each CTC status at the point of disease progression or week 8 was decreased or equal compared to that at the baseline, while blue indicates an increase. * p < 0.05.